Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24439929

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 Feb
First author
Wu YL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Feb;15(2):133-4. doi: 10.1016/S1470-2045(14)70002-6.
    note
    Source null
    related pmid
    24439930
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Apr;15(4):e148-9. doi: 10.1016/S1470-2045(13)70402-9.
    note
    Source null
    related pmid
    24694632
    relationship
    Comment in

Authors and identifiers

  1. name
    Wu YL
    type
    Author
  2. name
    Zhou C
    type
    Author
  3. name
    Hu CP
    type
    Author
  4. name
    Feng J
    type
    Author
  5. name
    Lu S
    type
    Author
  6. name
    Huang Y
    type
    Author
  7. name
    Li W
    type
    Author
  8. name
    Hou M
    type
    Author
  9. name
    Shi JH
    type
    Author
  10. name
    Lee KY
    type
    Author
  11. name
    Xu CR
    type
    Author
  12. name
    Massey D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wu YL
    type
    Author
  2. name
    Zhou C
    type
    Author
  3. name
    Hu CP
    type
    Author
  4. name
    Feng J
    type
    Author
  5. name
    Lu S
    type
    Author
  6. name
    Huang Y
    type
    Author
  7. name
    Li W
    type
    Author
  8. name
    Hou M
    type
    Author
  9. name
    Shi JH
    type
    Author
  10. name
    Lee KY
    type
    Author
  11. name
    Xu CR
    type
    Author
  12. name
    Massey D
    type
    Author
bibliography ids
  1. nci-bib-7bf54691ef146ffaca2b3e15
book metadata
content sha256
27f00da85a770199b8c4fa6545d9c0fc21b263540713a0cdc4b4fc2a5e1bbb84
document type
citation
dois
  1. 10.1016/S1470-2045(13)70604-1
electronic publication date
display
2014 Jan 15
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24439929
immutable id
pubmed:24439929@27f00da85a770199b8c4fa6545d9c0fc21b263540713a0cdc4b4fc2a5e1bbb84
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
213-22
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Feb;15(2):133-4. doi: 10.1016/S1470-2045(14)70002-6.
    note
    Source null
    related pmid
    24439930
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Apr;15(4):e148-9. doi: 10.1016/S1470-2045(13)70402-9.
    note
    Source null
    related pmid
    24694632
    relationship
    Comment in
outcomes validated
false
pmid
24439929
provenance
batch id
af10498814d931b53231
provider
NCBI PubMed ESummary
record sha256
49ddec2a8cdb6d53fe62180c87a4a1dd7f25ab7eb3c2c9d7d2afcf5403b023c4
response sha256
077a09272afe77e74d5ff01cb33335ddb8a638b7afbafb70ec20e837a0c85c7f
retrieved at
2026-09-09T23:47:00.193465+00:00
publication date
display
2014 Feb
precision
month
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24439929/
title
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Preserved source evidence · Not medical advice